title: Gene expression profile identifies a rare epithelioid variant case of pleomorphic liposarcoma carrying FUS-CHOP transcript.
abstract: OBJECTIVE
  To describe a tumour with morphological and immunophenotypic characteristics of epithelioid variant of pleomorphic liposarcoma. Pleomorphic liposarcoma is a very rare variant of liposarcoma defined morphologically by the presence of pleomorphic lipoblasts showing peculiar epithelial-like features that can be confused with primary or metastatic carcinoma.
  
  
  RESULTS
  Molecular analysis demonstrated for the first time the presence of FUS-CHOP transcript in this liposarcoma variant. Microarray analysis revealed a gene expression profile related to a more aggressive tumour type when compared with other myxoid/round cell liposarcomas.
  
  
  CONCLUSIONS
  The present data show that the epithelioid variant of pleomorphic liposarcoma represents a further variant of myxoid liposarcoma sharing the FUS-CHOP fusion transcript but carrying a distinct expression profile, in keeping with its aggressive clinical course.
authors.affiliation: FIRC Institute for Molecular Oncology Foundation, IFOM, Milano, Italy.
authors.forename: L
authors.initials: L
authors.lastname: De Cecco
authors.forename: M
authors.initials: M
authors.lastname: Gariboldi
authors.forename: J F
authors.initials: JF
authors.lastname: Reid
authors.forename: M S
authors.initials: MS
authors.lastname: Lagonigro
authors.forename: E
authors.initials: E
authors.lastname: Tamborini
authors.forename: V
authors.initials: V
authors.lastname: Albertini
authors.forename: S
authors.initials: S
authors.lastname: Staurengo
authors.forename: S
authors.initials: S
authors.lastname: Pilotti
authors.forename: M A
authors.initials: MA
authors.lastname: Pierotti
mesh_terms: D018952:Antigens, CD34 / Q000032:analysis; D015415:Biomarkers; D022762:CCAAT-Enhancer-Binding Proteins / Q000235:genetics*; D016000:Cluster Analysis; D003937:Diagnosis, Differential; D005260:Female; D005353:Fibronectins / Q000032:analysis; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D007633:Keratins / Q000032:analysis; D008080:Liposarcoma / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D008875:Middle Aged; D020411:Oligonucleotide Array Sequence Analysis; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D012334:RNA, Neoplasm / Q000235:genetics / Q000378:metabolism; D034702:RNA-Binding Protein FUS / Q000235:genetics*; D051499:Receptor, Fibroblast Growth Factor, Type 4; D017468:Receptors, Fibroblast Growth Factor / Q000032:analysis; D051742:Transcription Factor CHOP; D014158:Transcription, Genetic / Q000235:genetics; D014746:Vimentin / Q000032:analysis
chemical_list: D018952:Antigens, CD34; D015415:Biomarkers; C400901:CAM 5.2 antigen; D022762:CCAAT-Enhancer-Binding Proteins; D005353:Fibronectins; D015514:Oncogene Proteins, Fusion; D012334:RNA, Neoplasm; D034702:RNA-Binding Protein FUS; D017468:Receptors, Fibroblast Growth Factor; C106030:TLS-CHOP fusion protein, human; D014746:Vimentin; D051742:Transcription Factor CHOP; D007633:Keratins; C496371:FGFR4 protein, human; D051499:Receptor, Fibroblast Growth Factor, Type 4